Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prulifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prulifloxacin SCHEMBL13896543 | 1.00 | LMNA (1.00) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL1650794 | 1.00 | LMNA (1.00) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL1699755 | 1.00 | LMNA (1.00) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL7060281 | 1.00 | LMNA (1.00) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL136641 | 1.00 | LMNA (1.00) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL13822719 | 0.99 | LMNA (0.98) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL28660626 | 0.99 | LMNA (0.98) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL9673724 | 0.99 | LMNA (0.98) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL1231520 | 0.99 | LMNA (0.98) | LMNAPRKD3PIM1GSK3AGSK3B | |
| Prulifloxacin SCHEMBL9674383 | 0.96 | LMNA (0.92) | LMNAPRKD3PIM1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102307-A1 | ACELLULAR BLOOD ALTERNATIVE FOR TRANSFUSION AND ORGAN PERFUSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4673478-A2 | ANTIBODIES TO HTRA1 AND CONJUGATES THEREOF | Kodiak Sciences Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250352663-A1 | Nanoclusters Functionalized with Adenosine Triphosphate or an Analogue and Their Use | UNIV LELAND STANFORD JUNIOR (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250177558-A1 | Functionalized Nanoclusters and Their Use in Treating Bacterial Infections | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-06-05 | — | — | US | disclosed |
| US-12209240-B2 | Antisense antibacterial compounds and methods | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-28 | — | — | US | disclosed |
| EP-4486394-A1 | FUNCTIONALIZED NANOCLUSTERS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240316141-A1 | The Use of Thiourea and Thiourea Derivatives As Potentiators of Antibacterial Activity of Peptoids | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-09-26 | — | — | US | disclosed |
| WO-2024182318-A2 | ANTIBODIES TO HTRA1 AND CONJUGATES THEREOF | KODIAK SCIENCES INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| EP-3394262-B1 | ANTISENSE ANTIBACTERIAL COMPOUNDS AND METHODS | UNIV OREGON STATE (US) | 2024-08-28 | — | — | EP | disclosed |
| US-11998615-B2 | Functionalized nanoparticles and their use in treating bacterial infections | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-06-04 | — | — | US | disclosed |
| WO-2023164224-A1 | FUNCTIONALIZED NANOCLUSTERS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-08-31 | — | — | WO | disclosed |
| US-11707433-B2 | Methods and compositions for treating diabetic foot ulcers | PATHWAY DEVELOPMENT LLC (US) | 2023-07-25 | — | — | US | disclosed |
| EP-3765055-B1 | BACTERIAL-BINDING PEPTIDES FOR TREATMENT OF INFECTIOUS DISEASES AND RELATED INFLAMMATORY PROCESSES | SEPSIA THERAPEUTICS S L (ES) | 2023-06-07 | — | — | EP | disclosed |
| US-11660326-B2 | Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes | Sepsia Therapeutics, S.L. (ES) | 2023-05-30 | — | — | US | disclosed |
| US-20230149561-A1 | Functionalized Nanoparticles and Their Use in Treating Bacterial Infections | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-05-18 | — | — | US | disclosed |
| WO-2023288065-A1 | THE USE OF THIOUREA AND THIOUREA DERIVATIVES AS POTENTIATORS OF ANTIBACTERIAL ACTIVITY OF PEPTOIDS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20220339293-A1 | FUNCTIONALIZED NANOPARTICLES AND THEIR USE IN TREATING BACTERIAL INFECTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-10-27 | — | — | US | disclosed |
| EP-3996751-A1 | FUNCTIONALIZED NANOPARTICLES AND THEIR USE IN TREATING BACTERIAL INFECTIONS | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220135973-A1 | ANTISENSE ANTIBACTERIAL COMPOUNDS AND METHODS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-05 | — | — | US | disclosed |
| US-11293024-B2 | Antisense antibacterial compounds and methods | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660326-B2 | Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes | VIP, CD14, CCL2 | LMNA 3956/4885PRKD3 3886/4885PIM1 1745/4885 |
| US-12209240-B2 | Antisense antibacterial compounds and methods | RNGTT, POLRMT, NOP2 | LMNA 1602/4885PRKD3 3826/4885PIM1 4030/4885 |
| US-20220135973-A1 | ANTISENSE ANTIBACTERIAL COMPOUNDS AND METHODS | RNGTT, POLRMT, NOP2 | LMNA 1602/4885PRKD3 3826/4885PIM1 4030/4885 |
| US-11293024-B2 | Antisense antibacterial compounds and methods | RNGTT, DCLRE1B, POLRMT | LMNA 2667/4885PRKD3 3773/4885PIM1 3815/4885 |
| US-11707433-B2 | Methods and compositions for treating diabetic foot ulcers | PIK3C3, POLR1C, SLC5A2 | LMNA 3344/4885PRKD3 1971/4885PIM1 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.